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Peripheral Blood Progenitor Cell Transplantation 
Mobilked by r-metHuG-CSF (Filgrastim); a Less 
Costly Alternative to Autologous Bone Marrow 
Transplantation 
CA. Uyl-de Groot, D.J. Richel and F.F.H. Rutten 
In a retrospective study, we calculated the treatment costs of 63 patients who received either autologous bone 
marrow transplantatiou (ABMT) with recombinant human granulocyte colony-stimulating factor 
(r-metHuG-CSF) (6lgradm) (n=13) or without r-metHuG-CSF (n=22) or alternatively, peripheral blood 
progenitor cell (PBPC) transplantation mobilised by r-metHuG-CSF (n=28). The recovery of granulocytes, 
platelets and reticulocytes after PBPC was markedly accelerated as compared with ABMT with or without 
r-metHuG-CSF. The accelerated haematopoietic recovery was associated with a reduction in platelets and red 
blood cell transfusion requirements, with a reduction in episodes of fever and with earlier discharge from the 
hospital. This resulted in the average cost per treatment of the PBPC group being almost 30% lower than the 
treatment costs in the APMT groups. 
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colony-stimulating factor, filgrastim 
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INTRODUCTION 
BONE MARROW transplantation, as an adjunct to very intensive 
chemo- and radiotherapy, has significantly improved remission 
rates and survival in the treatment of acute leukaemias and 
malignant lymphomas. However, the procedure-associated risk 
of ~-W/O fatal complications and the adverse effect on patients’ 
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morbidity can be serious due to a pancytopenic period of 3-4 
weeks [ 11. Moreover, the costs of autologous as well as allogeneic 
bone marrow transplantation are high, and the additional burden 
that these treatments place on hospital budgets raises concern 
[2, 31. It is, therefore, relevant to not only assess the additional 
benefits to patients of new treatment options, but also to monitor 
their cost implications. 
Haematopoietic growth factors make it possible to accelerate 
the haematopoietic recovery after an autologous bone marrow 
transplantation (ABMT) and thereby reduce the therapy-related 
toxicity. As a result, a reduction in the initial hospitalisation 
and in the number of days on intravenous antibiotics was 
demonstrated [4]. However, although the use of haematopoietic 
growth factors caused a shortening of the neutropenic period, 
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the patients still had a median duration of severe neutropenia for 
2 weeks, and had more than 3 weeks of thrombocytopenia [4]. 
Therefore, additional strategies to further shorten this period 
are required. 
This study considers the costs of PBPC transplantation mobil- 
ised by r-metHuG-CSF (filgrastim) in comparison with ABMT 
without r-metHuG_CSF and AMBT with r-metHuG-CSF. 
In recent years, autologous transplantation of peripheral 
blood progenitor cells (PBPC) has attracted considerable interest 
The results are based on a retrospective study of detailed records 
because of the potential advantages in comparison with bone 
marrow, with respect to haematopoietic recovery [S-8]. PBPC 
of 63 patients. The perspective of the study was the hospital’s 
might be used in conjunction with haematopoietic growth factors 
to support haematopoietic recovery after high-dose chemo- 
point of view, that is, all hospital costs associated with PBPC 
therapy. 
and ABMT were considered. 
PATIENTS AND METHODS 
A total of 22 patients received ABMT without 
r-metHuG_CSF (six solid tumours and 16 malignant 
lymphomas), 13 patients recieved ABMT with r-metHuG-CSF 
(12 solid tumours and one malignant lymphoma) and 28 patients 
received PBPC with r-metHuG-CSF (19 solid tumours and nine 
malignant lymphomas) [9, lo]. The latter group included 6 
patients, who received a second PBPC reinfusion within 4 weeks. 
For the patients who received two reinfusions, the average costs 
of the two PBPC reinfusions were taken into account, as the aim 
of the cost analysis was to compare the costs of PBPC with 
the costs of ABMT. These patients received only one PBPC 
mobilisation and harvest; the costs of pretransplantation were 
not averaged. 
Patients’ characteristics are summarised in Table 1. The solid 
tumours mainly consisted of patients with breast cancer and 
germ cell tumours. The high-dose chemotherapy regimen of 
this group consisted of CTC (cyclophosphamide, thiotepa and 
carboplatin). The regimen for patients with malignant lym- 
phomas consisted of carmustine, cyclophosphamide, etoposide, 
and cytarabine (BEAC) or cyclophosphamide, carmustine and 
etoposide (CBV) or carmustine, etoposide, cytarabine and mel- 
phalan (BEAM). The proportion of solid tumours and malignant 
lymphomas was not equal across the three treatment groups. As 
all treatments consisted of similar high-dose chemotherapy, 
regardless of ABMT or PBPC, the costs of these regimen were 
considered as identical and disregarded in our analysis. 
The leucaphereses were performed with a leucapherese 
The PBPC mobilisation was performed on an outpatient 
machine (the CS300 of Cobe) on 3 consecutive days. Both 
setting. The lymphoma and germ cell tumour patients received 
one course of chemotherapy, namely cyclophosphamide (1 gi 
m*) on day 1 and etoposide (100 mg/m*) on days l-3 intra- 
the leucaphereses and the bone marrow were cryopreserved. 
venously. The breast cancer patients received one course of 
Additionally, a Hickman catheter was inserted. Three days after 
FEC (500 mg/m* 5-fluorouracil, 120 mg/m’ epidoxorubicin and 
500 mg/m* 
the administration of the high-dose chemotherapy, the stem cells 
cyclophosphamide). The chemotherapy was 
immediately followed by the administration of r-metHuG-CSF 
at a dosage of 300 ug subcutaneously, daily for 10 days. 
were reinfused. The patients received 300 kg r-metHuG-CSF 
daily until the granulocytes’ recovery was stable. 
The costs were considered separately for the pretransplan- 
tation and the transplantation period. The pretransplantation 
period included bone marrow (BM) or peripheral stem cell (PSC) 
harvest, cryopreservation and cultures, diagnostics, laborator- 
ies, hospitalisation, day-care department, medication, blood 
transfusions and the insertion of a Hickman catheter. The 
costs in the transplantation period related to days in hospital, 
laboratory services, diagnostics (mainly X-rays and ECGs), 
medication (antibiotics, anti-emetics, etc.) and blood trans- 
fusions. These costs have been registered through cost registry 
forms. Cost price studies have been carried out for all costs. The 
years of study were 1990-1992. 
Statistical methods included Kruska-Wallis tests for com- 
parisons of costs and for comparisons of time-to-event outcomes 
for the days iu hospital [ 111. 
Unit prices 
For each of the activities mentioned above, unit prices were 
determined reflecting the real use of resources. The year of study 
was 1992 (1 US$ i= 1.8 Dutch guilders). The unit prices are 
summarised in Table 2. 
The cost of hospital days and treatment in a day-care depart- 
ment were divided into direct and indirect costs. The direct 
costs concerned manpower (doctors, nurses, etc.) and materials 
(medical devices, supportive patient care, etc.). The indirect 
costs were related to overheads.. The cost of hospitalisation 
Table 1. Patients’ characteristics 
Control group 
ABMT 
ABMT + 
r-metHuG-CSF 
group 
PBPC + 
r-metHuG-CSF 
group 
Number of patients 
Median age, years (range) 
Male/Female 
Diagnosis 
Breast cancer 
Non-Hodgkin’s lymphoma 
Morbus Hodgkin’s 
Germ cell tumours 
Neuroblastoma 
Medulloblastoma 
22 13 28 (34*) 
30 (21-54) 32 (lg-44) 41 (lg-60) 
lb11 716 12/16 
1 
10 
6 
5 
0 
0 
11 
3 
6 
6 (11’) 
1 (2*) 
*6 patients received PBPC reinfusions: 5 patients with germ cell tumours and 1 patient with neuroblastoma. 
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amounted to approximately US$354 per day for normal haemato- 
logical care; the direct costs were US$238 and the indirect 
costs were US$116. Staying in a protected environment cost 
approximately US$552, divided into direct costs of US$398 and 
indirect costs of US$154. None of the patients was treated on an 
intensive care ward. A day of t:reatment in a day-care department 
cost approximately US$134 (a:pproximately 50% direct costs and 
50% indirect costs). 
l- 
0.6- 
p 0.6- 
P 
0” 
2 p 0.4- 
The output of laboratories in The Netherlands is measured in 
terms of a point system, and by each point (unit of output), a 
cost per unit or price may be associated, which differs across 
types of laboratories. The prices per point varied from US$O.62 
(biochemistry and haematology laboratories) to US$2.81 
(virology tests). The price of a routine test (including Hb, Ht, 
leucocytes and thrombocytes) amounted to 5.75 points and cost 
US$3.58. 
Days in hospital 
.- Control group - ASMT + G-CSF -- PSPC group 
For all other diagnostics, the Dutch tariff system has been 
used as an approximation of unit costs (an X-ray chest about 
US$31 and an ECG US$22>. The cost of the insertion of a 
Hickman catheter was US$504 (including the costs of the 
catheter). The drug prices used were wholesale prices. The costs 
of a 300~p,g vial of r-metHuG-CSF (intravenous) amounted to 
US$138.00. 
Figure 1. Mean length of hospitalisation. 
An additional study was pe.rformed to assess the average costs 
of both pretransplantation periods. The cost of BM harvest, 
cryopreservation and cultures was estimated at US$2043. In the 
PBPC group, the cost amounted to US$2740. The BM harvest 
was carried out on an inpatient basis, while the PCS harvest took 
place on an outpatient basis. The total costs of the pretransplan- 
tation period amounted to US$5006 for both ABMT groups, 
and to approximately US$5915 in the PBPC group. 
Table 2. Unit prices 
Clinical results 
RESULTS 
Items 
Unit cost 
WW 
Table 3 shows that haematological recovery was significantly 
accelerated with PBPC transplantation as compared with 
ABMT. The time to recovery of granulocytes to > 0.5~ 109/1 
was 15.0 days for the control group, 12.5 for the patients who 
received ABMT with r-metHuG-CSF and 8.0 for the PBPC 
group. For reticulocytes recovery to > lo%, it was 23.0 days in 
the control group, 25.5 in the group receiving ABMT with 
r-metHuG_CSF and 13.5 in the PBPC group. The median 
number of days for platelets recovery to > 20x 109/1 in the 
PBPC group was approximately half that of the control group 
and the ABMT with r-metHuG_CSF group (10.9 versus 20.2 
and 23.8 days, respectively). The median number of days for 
temperature recovery to > 38°C was also lower in the PBPC 
group: 2.5 versus 4.6 and 5.5 days in the ABMT with and 
without r-metHuG-CSF, respectively. 
Hospital stay 
Normal haematological care 
Protected environment 
Day-care department 
Laboratories 
Haematology (Hb, Ht, leucocyte, thrombocyte) 
Biochemistry (sodium, potassium, creatine, glucose) 
Urine 1 (pH, glucose, albumen, urobilin, bilirubin, 
sediment) 
Urine 2 (creatine, sodium, albumen, total protein) 
Cultures (blood/urine/sputum:1 
Virology fests 
Cytology (bone marrow/bronchus) 
Diagnostics 
X-ray chest 
X-ray sinus 
Electrocardiogram (ECG) 
Insertion Hickman catheter 
Total parenteral nutrition 
Platelet transfusions 
Red cell transfusions 
Drugs 
Filgrastim (r-metHuG_CSF) (300 pg i.v.) 
Antibiotics and other medication 
e.g. Ceftazidine 2000 mg i.v. 
Ciproxin 400 mg i.v. 
Ciproxin 500 mg oral 
Tienam 1500 mg i.v. 
Teicoplanin 400 mg i.v. 
Vancomycin 1000 mg i.v. 
Zofran 8 mg i.v. 
Zovirax 800 mg oral 
354.00 
552.00 
134.00 
3.58 
10.58 
12.47 
8.71 
20.50 
72.94 
42.59 
30.94 
36.92 
22.00 
504.00 
83.33 
74.44 
98.89 
138.00 
161.50 
77.22 
6.84 
70.83 
139.00 
66.14 
34.95 
5.97 
Hb, haemaglobin; Ht, haematocrit; i.v., intravenous. 
Results cost analysis 
Patients treated only with ABMT or with ABMT and 
r-metHuG_CSF had a mean hospital stay of 37.9 days (range 
19-70) and 36.2 days (range 24-68), respectively, while patients 
in the PBPC group had a mean stay in hospital of 22.4 days 
(range 17-38) (Figure 1). 
The most important cost items are summarised in Table 4. 
The patients in the control group stayed for 2 1 days in a protected 
environment, the ABMT with r-metHuG-CSF group 14 days 
and the PBPC group only 7 days. 
The accelerated haematopoietic recovery in the PBPC group 
was associated with a reduction in platelets and red blood cell 
transfusion requirements. r-metHuG-CSF was given for 19.4 
days (range 10-30) in the ABMT with r-metHuG_CSF group, 
and for 13.6 days (range MS) in the PBPC group. 
The costs of the three treatment groups are summarised in 
Table 5. The differences across the groups in the cost of the 
pretransplantation period were in favour of the ABMT groups; 
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Table 3. Clinical results 
Control group ABMT + PBPC + 
ABMT r-metHuG-CSF r-metHuG-CSF 
(n=22) group group 
(n= 13) (n=34) 
(median, range) (median, range) (median, range) 
Days to granulocytes recovery to > 0.5 x lo9 15.0 (11-17) 12.5 (gl8) 8.0 (611) 
Days to reticulocytes recovery to > 10% 23.0 (17-28) 25.5 (15-38) 13.5 (10-22) 
Days to thrombocytes recovery to> 20x lo9 20.2 (15-40) 23.8 (12-38) 10.9 (7-25) 
Days to temperature recovery to > 38°C 5.5 (5-12) 4.6 (O-12) 2.5 (O-12) 
US$SOO6 for both ABMT groups versus US$5915 for the PBPC 
group. However, the differences in the transplantation period 
were more pronounced and definitely in favour of the PBPC 
group. The hospitalisation costs amounted to approximately 
US$17578 for the ABMT group, US$15603 for the ABMT 
group with r-metHuG-CSF, and US$9318 for the PBPC group. 
Considering only costs, ABMT with r-metHuG-CSF does 
not seem to be a better treatment option than ABMT alone. 
Although the costs of hospitalisation were lower due to a shorter 
stay in hospital and in the protected environment, the costs 
of laboratory services, diagnostics, medication/nutrition and 
transfusions were higher. 
As compared with the other treatment groups, expenditure of 
the PBPC group was lower for all activities. The costs of 
hospitalisation decreased by more than 40%. The costs of 
medication/nutrition and transfusions were also significantly 
lower when compared to both ABMT groups, as were the costs 
of laboratory services and diagnostics. 
The costs of r-metHuG-CSF were zero in the control group, 
US$2703 in the ABMT with r-metHuG-CSF group, and 
US$1843 in the PBPC group. The costs of antibiotics and other 
medication decreased from US$3562 and US$3593, respectively, 
in the ABMT groups with and without r-metHuG-CSF, 
US$1590 in the PBPC group. Combining the costs of 
r-metHuG-CSF with medication and nutrition, the costs of 
medication were somewhat lower in the PBPC group (US$3433) 
as compared to the control group, but this difference was not 
statistically significant. The medication/nutrition costs in the 
ABMT with r-metHuG-CSF were remarkably higher 
(US$6296) as compared with the other two groups. 
The costs of transfusions decreased by more than 45%, from 
US$1584 and US$2209, respectively, in the ABMT groups to 
US$SSO in the PBPC group. 
The total costs in the transplantation period decreased by 
more than 35% in the PBPC group as compared with the other 
two groups. 
Although the costs of the pretransplantation period were 
higher in the PBPC group than in the ABMT groups, the total 
treatments costs decreased significantly; from US$30 592 in the 
control group and US$32443 in the ABMT with 
r-metHuG-CSF group to US$21809 in the PBPC group. 
A sensitivity analysis was performed to assess the effect of 
changes in the costs of hospital stay, transfusions and 
r-metHuG-CSF. The dominance of PBPC was robust, even if 
the savings in hospital days were not taken into account. 
DISCUSSION 
The aim of our study was to assess the costs of PBPC 
in comparison with ABMT. Previous studies have already 
demonstrated the feasibility of PBPC [5-lo]. Our results confirm 
that PBPC is an effective alternative to ABMT. ABMT is a costly 
procedure, as specialised care units and extensive supportive care 
are required. A reduction in costs through the administration of 
haematopoietic growth factors (HGF) could not be demonstrated 
in our study. Our results show a reduction of hospital days, but 
the costs of medication, due to the additional costs of the 
r-metHuG-CSF, and transfusions were still higher in the ABMT 
with r-metHuG-CSF group as compared with ABMT alone. 
However, for almost all activities, PBPC was cheaper than 
ABMT with or without r-metHuG-CSF. 
Often new treatment options show additional benefits to 
patients, but also add to the health care bill. To say that this will 
not be true for PBPC transplantation would be a premature 
statement as one may expect this new option, which constitutes 
a lighter burden both to the patient and to the financial manager 
in the hospital, to diffuse more rapidly in cancer treatment than 
Table 4. Most important cost items 
Number of hospital stay in days 
Number of platelet transfusions 
Number of red cell transfusions 
Days of r-metHuG-CSF treatment 
Control group 
ABMT 
(n=22) 
(mean, range) 
37.9 (19-70) 
47.1(18-179) 
10.1 (3-21) 
- 
ABMT + 
r-metHuC_CSF 
group 
(n=13) 
(mean, range) 
36.2 (24-68) 
70.8 (10-161) 
13.5 (4-35) 
19.4 (l&30) 
PBPC + 
r-metHuG-CSF 
group 
(n=28) 
(mean, range) 
22.4 (17-38) 
26.7 (9-100) 
6.2 (l-29) 
13.6 (8-45) 
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Table 5. The average costs of ABMT with and without r-metHuG-CSF in comparison with PBPC 
transplantation (in US$) 
Period 
Control group 
ABMT 
(n=22) 
ABMT + PBPC + 
r-metHuG_CSF r-metHuG-CSF 
group group 
(n= 13) (n=28) 
Pretransplanation 
BM or PSC harvest, cryopreservation 
and cultures 
Diagnostics, laboratories 
Hospitalisation/outpatient visits 
Medication/transfusions 
Hickman c:atheter 
Total pretransplantation 
Transplantation 
Hospitalisation 
Laboratory 
Diagnostic:s 
Medicatiodnutrition 
R-metHuG-CSF (flgrastim) 
Transfusions 
Total transpltiitation 
Total treatment costs 
2043 2043 2740 
885 885 875 
1367 1367 402 
191 191 1378 
520 520 520 
5006 5006 5915 
17 578 15 603 9318t 
2626 3006 2123* 
236 323 170* 
3562 3593 159Ot 
ot 2703 1843 
1584 2209 850* 
25 586 27 437 15 894t 
30 592 32 443 21809t 
*Kruskal-Wallis test: F < 0.05. t Kruskal-Wallis test: P < 0.01. 1 US$ = 1.8 Dutchguilders. 
ABMT. Our results suggest, however, that for patients with 
malignant lymphomas or solid tumours, who receive high-dose 
chemotherapy, PBPC transplantation is more cost-effective than 
ABMT. Further research will be needed to confirm this result. 
Moreover, as ABMT is associated with high mortality and 
morbidity rates, it may be worth also taking the effectiveness, 
including patients’ quality of life, of PBPC into account. A 
“piggy-back” economic analysis (an economic evaluation perfor- 
med alongside a clinical trial) may be combined with future 
prospective trials to confirm the dominance of PBPC over ABMT 
in the patient groups considered here. 
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